Blood Cancer
E1910
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
STATUS: CLOSED
Description
This randomized phase III trial studied combination chemotherapy with blinatumomab to see how well it worked compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase (ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The trial found that the addition of blinatumomab to consolidation chemotherapy in adult patients in MRD-negative remission from BCP-ALL significantly improved overall survival. This finding led to an FDA approval for blinatumomab.
Selected News Stories
Video: Behind the ECOG-ACRIN E1910 Trial: Blinatumomab in B-ALL Targeted Oncology
Blinatumomab Improves 3-Year Survival in B-ALL vs Chemotherapy Targeted Oncology
Blinatumomab Significantly Improves OS in Newly Diagnosed B-ALL Patients Who Are MRD Negative After Initial Treatment American Journal of Managed Care®
Blinatumomab Further Improves Survival Among Patients With B-Lineage ALL and a Good Prognosis The ASCO Post
The ECOG-ACRIN Cancer Research Group designed and conducted this trial with funding from the National Cancer Institute through its National Clinical Trials Network.
